Quick Win by The Algorithm: Insys Therapeutics Stock Price Soars After FDA Fast Track Designation

Quick Win by The Algorithm



Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Throughout December, 2017, Insys experienced a significant one-month share price increase of 82%. The rally began on December 19th, when Insys announced the initiation of a Phase II clinical trial to assess its cannabidiol (CBD) oral solution in epileptic children with treatment-resistant absence or seizures.

On December 26th, 2017, Insys released a statement expressing its progress in developing drugs derived from marijuana cannabinoids, ultimately adding to its dramatic price rise. The Food and Drug Administration (FDA) awarded Insys a Fast Track designation to its cannabidiol research for use in treating Prader-Willi syndrome – a rare, debilitating genetic disorder associated with an insatiable appetite in children often resulting in complications including morbid obesity and type 2 diabetes. Clinical development for this program is expected to initiate in the late first quarter of 2018, and the Fast Track designation will facilitate the development by expediting the review process and offering improved communication between the FDA and Insys. Currently, no approved treatments are available the market for Prader-Willi syndrome.

On December 26th, 2017, I Know First issued a bullish 7-day forecast for INSYS Therapeutics, Inc. (Nasdaq: INSY). The forecast illustrated a signal of 23.47 and a predictability of 0.11. In accordance with the forecast, INSY’s stock returned 61.94% over this period, highlighting another quick win by the I Know First algorithm.Current I Know First subscribers received this bullish INSY forecast on December 26th, 2017


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.